Inactive Instrument

Highlights Forma Therapeutics Holdings, Inc.

Equities

FMTX

US34633R1041

Highlights

Unlock all the news: Be the first to know and act before the market!

Novo Nordisk Completes Acquisition of Forma Therapeutics; Forma Shares to be Delisted	14/10/22	MT
Novo Nordisk Completes Acquisition of Forma Therapeutics	14/10/22	MT
Novo Nordisk A/S (CPSE:NOVO B) completed the acquisition of Forma Therapeutics Holdings, Inc. (NasdaqGM : FMTX) from RA Capital Management, L.P. and others.	12/10/22	CI
Forma Therapeutics Shares Surge on Takeover by Novo Nordisk	01/09/22	DJ
Novo Nordisk to Acquire Forma Therapeutics in $1.1 Billion Deal	01/09/22	MT
Novo Nordisk To Acquire US-based Forma Therapeutics For $1 Billion	01/09/22	MT
Novo Nordisk to Buy Forma Therapeutics for $1.1 Billion	01/09/22	DJ
Novo Nordisk to acquire Forma Therapeutics in $1.1. billion deal	01/09/22	RE
Novo Nordisk A/S (CPSE:NOVO B) entered into a definitive agreement to acquire Forma Therapeutics Holdings, Inc. from RA Capital Management, L.P. and others for approximately $990 million	31/08/22	CI
Forma Therapeutics Holdings Q2 Net Loss Widens	05/08/22	MT
Forma Therapeutics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	05/08/22	CI
Rigel Pharmaceuticals, Inc. and Forma Therapeutics Holdings, Inc. Announces Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid Leukemia	02/08/22	CI
Forma Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	06/05/22	CI
Forma Therapeutics Posts Wider Q4 Loss	01/03/22	MT
Forma Therapeutics Holdings, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	01/03/22	CI
Forma Therapeutics Holdings, Inc.'s Investigational Olutasidenib in Combination with Azacitidine Yields Durable Complete Remission in Patients with mIDH1 Acute Myeloid Leukemia	16/12/21	CI
Forma Therapeutics Holdings, Inc.’s Investigational Once-Daily Etavopivat Significantly Improved Anemia and Red Blood Cell Health in Patients with Sickle Cell Disease	11/12/21	CI
Forma Therapeutics Posts Wider Q3 Loss Amid Higher Spending	12/11/21	MT
Forma Therapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	12/11/21	CI
Forma Therapeutics Holdings, Inc. Announces Positive Initial Results from A Phase 1 Trial of Its Novel CBP/P300 Inhibitor, the Oral Small Molecule FT-7051	07/10/21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Forma Therapeutics Holdings, Inc.

Equities

FMTX

US34633R1041

Highlights

Filters